NCT01883167View on ClinicalTrials.gov

RDEA3170 and Febuxostat Drug Interaction Study

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

December 31, 2013

Conditions
Healthy
Interventions
DRUG

RDEA3170 10 mg

RDEA3170 10 mg once daily (qd)

DRUG

Febuxostat 40 mg

Febuxostat 40 mg qd

DRUG

placebo

placebo qd

Trial Locations (1)

49007

Kalamazoo

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY

NCT01883167 - RDEA3170 and Febuxostat Drug Interaction Study | Biotech Hunter | Biotech Hunter